Pilar Obat · Watchdog Obat Indonesia

Obat mana yang Indonesia belum kaji lewat Fornas?

Pilar ini membandingkan dua sumber bukti internasional — NICE Drug HTA (UK, gold standard cost-effectiveness) dan WHO Essential Medicines List (obat esensial WHO) — dengan dua sumber Indonesia: Fornas (formularium nasional Kemenkes RI) dan INAPROC (e-katalog procurement aktif). Output utamanya: HTA priority list — obat kandidat kaji untuk Komite HTA Indonesia.

1Sumber bukti internasional

Bukti cost-effective + esensial

· NICE Drug HTA (924 appraisal TA/HST)
· WHO Essential Medicines List + UHC

2Bandingkan Indonesia

Apa yang sudah dijamin & dijual?

· Fornas (formularium Kemenkes)
· INAPROC (e-katalog procurement)

3Output advokasi

HTA priority list

· Prioritas 1 (NICE ∩ EML, ✗Fornas)
· Prioritas 2 (NICE atau EML, ✗Fornas)

1366 obat unik (lintas-sumber)65 Prioritas 1715 Prioritas 2

Sumber data

Berapa obat per sumber?

Universe: 1.366 obat unik

Fornas

503

/ 1.366

Formularium Nasional Indonesia

37% dari universe

e-Katalog

412

/ 1.366

INAPROC produk aktif

30% dari universe

WHO EML

806

/ 1.366

Essential Medicines List + UHC

59% dari universe

NICE

433

/ 1.366

TA + HST appraisals

32% dari universe

HTA Priority

Daftar prioritas kaji-HTA Indonesia

Berbasis kombinasi sumber bukti internasional vs ada-tidaknya di Fornas

Prioritas 1

Ada di NICE DAN WHO EML. Belum di Fornas. Dua sumber bukti internasional independen menyebut — kandidat HTA paling kuat.

Lihat daftar →

Prioritas 2

715

Ada di salah satu (NICE atau WHO EML). Belum di Fornas. Satu sumber bukti internasional menyebut — layak dievaluasi.

Lihat daftar →

Tidak prioritas

586

Sudah di Fornas, atau tidak ada referensi NICE/WHO EML sama sekali. Tidak masuk daftar HTA priority saat ini.

Lihat daftar →

Pemetaan lintas-sumber

Persebaran obat: NICE × WHO EML × Fornas

Diagram Venn 3-arah · deskriptif, bukan penilaian

Universe lintas-sumber: 1.283 obat unik dengan ATC code di setidaknya satu dari NICE, WHO EML, atau Fornas. (83 obat lain hanya muncul di INAPROC e-katalog tanpa referensi tiga sumber utama.)

HTA Prioritas 165 obat. Ada di NICE dan WHO EML, belum di Fornas. Dua sumber bukti internasional independen menyebut, Indonesia belum mengadopsi.

HTA Prioritas 2715 obat. Ada di NICE ATAU WHO EML, belum di Fornas. (NICE-only: 309 · EML-only: 406).

NICE only: 309
EML only: 406
Fornas only: 151
NICE + EML + Fornas: 42

Cek internal Indonesia: apakah Fornas (formularium) selaras dengan INAPROC e-katalog (procurement)? · Lihat gap Fornas vs INAPROC →

Master list

Tabel obat lintas-sumber

Klik kode ATC untuk drug detail · ketik di kolom cari untuk instant filter

1.366obat cocokmenampilkan 300 teratas

ATC	Nama generik	Kelas	NICE	EML	Fornas	e-Kat	Source combination	HTA priority
L01FF02	pembrolizumab	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01FF01	nivolumab	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01FF05	atezolizumab	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01FG01	bevacizumab	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01EL01	ibrutinib	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01FC01	daratumumab	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01FF03	durvalumab	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L04AB04	adalimumab	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
A10BK01	dapagliflozin	Alimentary tract and metabolism	●	●	○	○	NICE + EML	Prioritas 1
A10BK03	empagliflozin	Alimentary tract and metabolism	●	●	○	○	NICE + EML	Prioritas 1
L01EL03	zanubrutinib	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L02BB04	enzalutamide	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01EB04	osimertinib	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01EC02	dabrafenib	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01FF06	cemiplimab	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01FX07	blinatumomab	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L03AB10	peginterferon alfa-2b	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L04AB02	infliximab	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L04AC05	ustekinumab	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
A10BK02	canagliflozin	Alimentary tract and metabolism	●	●	○	○	NICE + EML	Prioritas 1
B01AF02	apixaban	Blood and blood forming organs	●	●	○	○	NICE + EML	Prioritas 1
L01EA02	dasatinib	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01ED01	crizotinib	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01EF02	ribociclib	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01EF03	abemaciclib	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01FD02	pertuzumab	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01FF07	dostarlimab	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01FF09	tislelizumab	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01XL03	axicabtagene ciloleucel	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01XL04	tisagenlecleucel	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01XL08	lisocabtagene maraleucel	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L02BX03	abiraterone	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L04AB05	certolizumab pegol	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L04AB06	golimumab	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
A10BJ02	liraglutide	Alimentary tract and metabolism	●	●	○	○	NICE + EML	Prioritas 1
A10BJ06	semaglutide	Alimentary tract and metabolism	●	●	○	○	NICE + EML	Prioritas 1
A10BX16	tirzepatide	Alimentary tract and metabolism	●	●	○	○	NICE + EML	Prioritas 1
B01AF03	edoxaban	Blood and blood forming organs	●	●	○	○	NICE + EML	Prioritas 1
L01BB04	cladribine	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01BC07	azacitidine	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01EC03	encorafenib	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01EF01	palbociclib	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01FX04	ipilimumab	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L04AG08	ocrelizumab	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
N07BB04	naltrexone	Nervous system	●	●	○	●	NICE + EML	Prioritas 1
R07AX02	ivacaftor	Respiratory system	●	●	○	○	NICE + EML	Prioritas 1
B03XA03, B03XA01, B03XA02	erythropoiesis-stimulating agents	Blood and blood forming organs	●	●	○	○	NICE + EML	Prioritas 1
J05AH02	oseltamivir	Antiinfectives for systemic use	●	●	○	○	NICE + EML	Prioritas 1
J05AP51	sofosbuvir and ledipasvir	Antiinfectives for systemic use	●	●	○	○	NICE + EML	Prioritas 1
J05AP57	glecaprevir and pibrentasvir	Antiinfectives for systemic use	●	●	○	○	NICE + EML	Prioritas 1
L01EC01	vemurafenib	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01EE01	trametinib	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01EE02	cobimetinib	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01EK01	axitinib	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01FE02	panitumumab	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01FF13	toripalimab	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L01XX27	arsenic trioxide	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L04AC03	anakinra	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
L04AE01	fingolimod	Antineoplastic and immunomodulating agents	●	●	○	○	NICE + EML	Prioritas 1
M09AX10	risdiplam	Musculo-skeletal system	●	●	○	○	NICE + EML	Prioritas 1
N02CD01	erenumab	Nervous system	●	●	○	○	NICE + EML	Prioritas 1
N02CD02	galcanezumab	Nervous system	●	●	○	○	NICE + EML	Prioritas 1
N02CD03	fremanezumab	Nervous system	●	●	○	○	NICE + EML	Prioritas 1
N02CD05	eptinezumab	Nervous system	●	●	○	○	NICE + EML	Prioritas 1
N07BA03	varenicline	Nervous system	●	●	○	○	NICE + EML	Prioritas 1
L01XK01	olaparib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AF03	upadacitinib	Antineoplastic and immunomodulating agents	●	○	○	●	NICE	Prioritas 2
D11AH05	dupilumab	Dermatologicals	●	○	○	○	NICE	Prioritas 2
L01EX07	cabozantinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XX44	aflibercept	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX09	nintedanib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XX52	venetoclax	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AF01	tofacitinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX05	regorafenib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX22	selpercatinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FA03	obinutuzumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FF04	avelumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FG02	ramucirumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AC16	guselkumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AC18	risankizumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AC21	bimekizumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AF02	baricitinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AJ02	ravulizumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
R03DX09	mepolizumab	Respiratory system	●	○	○	○	NICE	Prioritas 2
A10AB01	insulin (human)	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
L01BC08	decitabine	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01CE01	topotecan	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EM01	idelalisib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FC02	isatuximab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XG02	carfilzomib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XK02	niraparib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L02BB06	darolutamide	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L02BX04	relugolix	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AC13	ixekizumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AG05	vedolizumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AJ01	eculizumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
M05BX04	denosumab	Musculo-skeletal system	●	○	○	○	NICE	Prioritas 2
N03AX24	cannabidiol	Nervous system	●	○	○	○	NICE	Prioritas 2
R03DX05	omalizumab	Respiratory system	●	○	○	○	NICE	Prioritas 2
S01AD02	trifluridine	Sensory organs	●	○	○	○	NICE	Prioritas 2
S01LA09	faricimab	Sensory organs	●	○	○	○	NICE	Prioritas 2
A03AC02	dimethylaminopropionylphenothiazine	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A06AH01	methylnaltrexone bromide	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A08AA02	fenfluramine	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A08AA12	setmelanotide	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A10BK04	ertugliflozin	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AB14	sebelipase alfa	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
B02BX08	avatrombopag	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B03XA06	luspatercept	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B06AX05	exagamglogene autotemcel	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
G03XC01	raloxifene	Genito-urinary system and sex hormones	●	○	○	○	NICE	Prioritas 2
G04BD12	mirabegron	Genito-urinary system and sex hormones	●	○	○	○	NICE	Prioritas 2
H01CC04	linzagolix	Systemic hormonal preparations	●	○	○	○	NICE	Prioritas 2
J05AJ04	cabotegravir	Antiinfectives for systemic use	●	○	○	○	NICE	Prioritas 2
J05AX18	letermovir	Antiinfectives for systemic use	●	○	○	○	NICE	Prioritas 2
J05AX25	baloxavir marboxil	Antiinfectives for systemic use	●	○	○	○	NICE	Prioritas 2
L01AB02	treosulfan	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01AD01	carmustine	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EA04	bosutinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01ED02	ceritinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01ED04	brigatinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01ED05	lorlatinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EM04	duvelisib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX01	sunitinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX10	midostaurin	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX14	entrectinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX18	avapritinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX13	enfortumab vedotin	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX14	polatuzumab vedotin	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX15	belantamab mafodotin	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX17	sacituzumab govitecan	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX18	amivantamab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX27	epcoritamab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX28	glofitamab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XK03	rucaparib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XK04	talazoparib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XL06	brexucabtagene autoleucel	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XL07	idecabtagene vicleucel	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XM02	ivosidenib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XX66	selinexor	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L02BB05	apalutamide	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AA24	abatacept	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AA32	apremilast	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AC14	sarilumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AC24	mirikizumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AE02	ozanimod	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AF04	filgotinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AG03	natalizumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AG04	belimumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AJ08	iptacopan	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L04AX06	pomalidomide	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
M05BX05	burosumab	Musculo-skeletal system	●	○	○	○	NICE	Prioritas 2
M09AX02	chondrocytes, autologous	Musculo-skeletal system	●	○	○	○	NICE	Prioritas 2
M09AX09	onasemnogene abeparvovec	Musculo-skeletal system	●	○	○	○	NICE	Prioritas 2
N01AX14	esketamine	Nervous system	●	○	○	○	NICE	Prioritas 2
N02CD06	rimegepant	Nervous system	●	○	○	○	NICE	Prioritas 2
N06BA14	solriamfetol	Nervous system	●	○	○	○	NICE	Prioritas 2
N07XX18	vutrisiran	Nervous system	●	○	○	○	NICE	Prioritas 2
R03DX10	benralizumab	Respiratory system	●	○	○	○	NICE	Prioritas 2
S01LA06	brolucizumab	Sensory organs	●	○	○	○	NICE	Prioritas 2
V03AB38	andexanet alfa	Various	●	○	○	○	NICE	Prioritas 2
A01AA01	sodium fluoride	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A03BA04	belladonna total alkaloids	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A05AA04	obeticholic acid	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A05AX05	odevixibat	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A05AX06	elafibranor	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A06AH03	naloxegol	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A06AH05	naldemedine	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A06AX02	carbon dioxide producing drugs	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A06AX05	prucalopride	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A07AA11	rifaximin	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AA07	metreleptin	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AB12	elosulfase alfa	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AB13	asfotase alfa	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AB15	velmanase alfa	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AB17	cerliponase alfa	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AB20	pegunigalsidase alfa	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AB21	atidarsagene autotemcel	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AB22	avalglucosidase alfa	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AB23	cipaglucosidase alfa	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AB24	pegzilarginase	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AB25	olipudase alfa	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AB26	eladocagene exuparvovec	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AX07	sapropterin	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AX08	teduglutide	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AX10	eliglustat	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AX14	migalastat	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AX16	givosiran	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AX18	lumasiran	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
A16AX19	fosdenopterin	Alimentary tract and metabolism	●	○	○	○	NICE	Prioritas 2
B01AC22	prasugrel	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B01AC25	cangrelor	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B01AD11	tenecteplase	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B01AX07	caplacizumab	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B02BD16	etranacogene dezaparvovec	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B02BX04	romiplostim	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B02BX07	lusutrombopag	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B02BX09	fostamatinib	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B02BX10	concizumab	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B02BX11	marstacimab	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B03XA05	roxadustat	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B03XA08	vadadustat	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B06AC05	lanadelumab	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B06AC06	berotralstat	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B06AC07	garadacimab	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
B06AX04	mitapivat	Blood and blood forming organs	●	○	○	○	NICE	Prioritas 2
C01BB02	mexiletine	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C01BD07	dronedarone	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C01BG11	vernakalant	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C01CX09	angiotensin ii	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C01DX22	vericiguat	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C01EB24	mavacamten	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C01EB25	acoramidis	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C03DA05	finerenone	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C03XA01	tolvaptan	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C05BA04	pentosan polysulfate sodium	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C09DX04	valsartan and sacubitril	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C09XX01	sparsentan	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C10AX09	ezetimibe	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C10AX13	evolocumab	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C10AX14	alirocumab	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C10AX15	bempedoic acid	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C10AX16	inclisiran	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C10AX17	evinacumab	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
C10AX18	volanesorsen	Cardiovascular system	●	○	○	○	NICE	Prioritas 2
D02BB02	afamelanotide	Dermatologicals	●	○	○	○	NICE	Prioritas 2
D03AX13	betulae cortex	Dermatologicals	●	○	○	○	NICE	Prioritas 2
D05AX06	roflumilast	Dermatologicals	●	○	○	○	NICE	Prioritas 2
D10AX06	clascoterone	Dermatologicals	●	○	○	○	NICE	Prioritas 2
D11AH04	alitretinoin	Dermatologicals	●	○	○	○	NICE	Prioritas 2
D11AH06	crisaborole	Dermatologicals	●	○	○	○	NICE	Prioritas 2
D11AH08	abrocitinib	Dermatologicals	●	○	○	○	NICE	Prioritas 2
D11AH10	lebrikizumab	Dermatologicals	●	○	○	○	NICE	Prioritas 2
D11AH11	delgocitinib	Dermatologicals	●	○	○	○	NICE	Prioritas 2
D11AH12	nemolizumab	Dermatologicals	●	○	○	○	NICE	Prioritas 2
G02CX06	fezolinetant	Genito-urinary system and sex hormones	●	○	○	○	NICE	Prioritas 2
G04BD15	vibegron	Genito-urinary system and sex hormones	●	○	○	○	NICE	Prioritas 2
G04BE08	tadalafil	Genito-urinary system and sex hormones	●	○	○	○	NICE	Prioritas 2
H01AC07	somapacitan	Systemic hormonal preparations	●	○	○	○	NICE	Prioritas 2
H01AC08	somatrogon	Systemic hormonal preparations	●	○	○	○	NICE	Prioritas 2
H02AB18	vamorolone	Systemic hormonal preparations	●	○	○	○	NICE	Prioritas 2
H05AA04	abaloparatide	Systemic hormonal preparations	●	○	○	○	NICE	Prioritas 2
H05BX01	cinacalcet	Systemic hormonal preparations	●	○	○	○	NICE	Prioritas 2
H05BX04	etelcalcetide	Systemic hormonal preparations	●	○	○	○	NICE	Prioritas 2
J05AE30	nirmatrelvir and ritonavir	Antiinfectives for systemic use	●	○	○	○	NICE	Prioritas 2
J05AF08	adefovir dipivoxil	Antiinfectives for systemic use	●	○	○	○	NICE	Prioritas 2
J05AP10	elbasvir	Antiinfectives for systemic use	●	○	○	○	NICE	Prioritas 2
J05AP52	dasabuvir, ombitasvir, paritaprevir and ritonavir	Antiinfectives for systemic use	●	○	○	○	NICE	Prioritas 2
J05AX10	maribavir	Antiinfectives for systemic use	●	○	○	○	NICE	Prioritas 2
J05AX28	bulevirtide	Antiinfectives for systemic use	●	○	○	○	NICE	Prioritas 2
J06AA04	botulinum antitoxin	Antiinfectives for systemic use	●	○	○	○	NICE	Prioritas 2
J06BD03	tixagevimab and cilgavimab	Antiinfectives for systemic use	●	○	○	○	NICE	Prioritas 2
J07AP01	typhoid, oral, live attenuated	Antiinfectives for systemic use	●	○	○	○	NICE	Prioritas 2
L01AA05	chlormethine	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01CA05	vinflunine	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01CD04	cabazitaxel	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01CX01	trabectedin	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01DB11	pixantrone	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EA06	asciminib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EB07	dacomitinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EE04	selumetinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EG01	temsirolimus	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EG04	sirolimus	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EH02	neratinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EH03	tucatinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EJ02	fedratinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EJ04	momelotinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EK03	tivozanib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EK04	fruquintinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EL02	acalabrutinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EM03	alpelisib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EN01	erdafitinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EN02	pemigatinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EN04	futibatinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EP01	capmatinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EP02	tepotinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX02	sorafenib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX04	vandetanib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX11	quizartinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX12	larotrectinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX13	gilteritinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX19	ripretinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX23	pralsetinib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01EX27	capivasertib	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FA02	ofatumumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FB01	inotuzumab ozogamicin	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FE03	necitumumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX02	gemtuzumab ozogamicin	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX06	dinutuximab beta	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX08	elotuzumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX09	mogamulizumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX12	tafasitamab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX22	loncastuximab tesirine	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX24	teclistamab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX25	mosunetuzumab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX29	talquetamab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX31	zolbetuximab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX32	elranatamab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01FX33	tarlatamab	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2
L01XD07	padeliporfin	Antineoplastic and immunomodulating agents	●	○	○	○	NICE	Prioritas 2